High Growth Stocks by ST Score
Top 30 results, ranked from our full US coverage.
These companies earn a growth grade of B or better, based on how their revenue, earnings and cash flow are expanding compared with sector peers.
Ranking by ST Score keeps the emphasis on growth that is backed by profitability and a workable balance sheet rather than growth at any cost.
Check the valuation grade column too — fast growth is often already reflected in the share price.
| # | Symbol | Company | Sector | Price | Market cap | Grade | Analysts | ST Score |
|---|---|---|---|---|---|---|---|---|
| 1 | PERF | Perfect Corp. | Technology | $1.93 | $196.6M | A- | Hold | 79.5 |
| 2 | CAAS | China Automotive Systems, Inc. | Consumer Cyclical | $5.08 | $153.3M | A- | — | 78.9 |
| 3 | JCSE | JE Cleantech Holdings Limited | Industrials | $1.46 | $7.7M | A- | — | 78.8 |
| 4 | JVA | Coffee Holding Co., Inc. | Consumer Defensive | $4.14 | $23.6M | A- | Buy | 78.4 |
| 5 | EXG | Eaton Vance Tax-Managed Global Diversified Equity Income Fund | Financial Services | $9.62 | $2.94B | A- | Hold | 78.3 |
| 6 | OMSE | OMS Energy Technologies Inc. | Energy | $4.37 | $185.5M | B+ | — | 74.8 |
| 7 | CLIK | Click Holdings Limited | Industrials | $1.22 | $771,285 | B+ | — | 74.7 |
| 8 | VOXR | Vox Royalty Corp. | Basic Materials | $5.72 | $394.1M | B+ | Buy | 73.6 |
| 9 | SPTX | Seaport Therapeutics, Inc. Common Stock | Healthcare | $21.39 | $1.15B | B+ | Buy | 73.5 |
| 10 | TCMD | Tactile Systems Technology, Inc. | Healthcare | $22.20 | $500.7M | B+ | Buy | 73.4 |
| 11 | GRVY | Gravity Co., Ltd. | Technology | $69.35 | $481.9M | B+ | — | 73.1 |
| 12 | INSP | Inspire Medical Systems, Inc. | Healthcare | $76.78 | $2.22B | B+ | Hold | 73.0 |
| 13 | COAG | Hemab Therapeutics Holdings, Inc. Common Stock | Healthcare | $37.97 | $1.77B | B+ | Buy | 72.4 |
| 14 | IOSP | Innospec Inc. | Basic Materials | $93.15 | $2.29B | B+ | Hold | 72.3 |
| 15 | LPG | Dorian LPG Ltd. | Energy | $58.15 | $2.49B | B+ | Hold | 72.3 |
| 16 | MU | Micron Technology, Inc. | Technology | $1,015.80 | $1.15T | B+ | Buy | 72.0 |
| 17 | ODC | Oil-Dri Corporation of America | Basic Materials | $88.88 | $1.24B | B+ | — | 71.2 |
| 18 | FENC | Fennec Pharmaceuticals Inc. | Healthcare | $10.62 | $368.9M | B+ | Buy | 70.9 |
| 19 | HTLM | HomesToLife Ltd | Consumer Cyclical | $1.97 | $176.7M | B+ | — | 70.8 |
| 20 | IT | Gartner, Inc. | Technology | $185.78 | $12.44B | B+ | Hold | 70.6 |
| 21 | CHCI | Comstock Holding Companies, Inc. | Real Estate | $20.07 | $201.5M | B+ | — | 70.3 |
| 22 | IX | ORIX Corporation | Financial Services | $39.30 | $43.63B | B+ | — | 70.3 |
| 23 | RL | Ralph Lauren Corporation | Consumer Cyclical | $335.10 | $20.44B | B+ | Buy | 70.3 |
| 24 | MNST | Monster Beverage Corporation | Consumer Defensive | $44.71 | $87.45B | B+ | Buy | 70.2 |
| 25 | UAN | CVR Partners, LP | Basic Materials | $133.91 | $1.42B | B+ | Hold | 70.2 |
| 26 | INVX | Innovex International, Inc. | Energy | $28.80 | $2.01B | B+ | Buy | 69.7 |
| 27 | PLTR | Palantir Technologies Inc. | Technology | $177.64 | $407.87B | B+ | Buy | 69.7 |
| 28 | HL | Hecla Mining Company | Basic Materials | $18.92 | $12.69B | B+ | Hold | 69.6 |
| 29 | ABUS | Arbutus Biopharma Corp | Healthcare | $5.00 | $987.7M | B+ | Buy | 69.5 |
| 30 | NUTX | Nutex Health, Inc. | Healthcare | $208.79 | $1.44B | B+ | Buy | 69.5 |
Want to change the thresholds? Open the full stock screener and adjust any of the 100+ filters.
Frequently asked questions
What counts as a high growth stock?
A company expanding revenue and earnings faster than most of its sector peers. Our growth grade measures that on a relative curve from A+ to F.
Are growth stocks riskier?
They are often more volatile, because much of their value rests on future results. Disappointing figures can reprice the shares sharply.
Why do some high-growth names have weak valuation grades?
Strong growth usually attracts a premium multiple, so a high growth grade and a low valuation grade frequently appear together.
How often is the growth grade updated?
With each data run, as new quarterly results and analyst estimates arrive.
Popular screens
Ready-made lists built from the same data — no filters to set.